Pilot Study to Examine Correlation of Nab-Paclitaxel/Gemcitabine Pharmacokinetics with Cachexia
Brief description of study
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: pancreatic cancer
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria
Patients with locally advanced, metastatic or recurrent pancreatic ductal adenocarcinoma (PDAC)
Planned systemic first or second line therapy with Nab-P/G
ECOG Performance Status 0-2
Ability to provide written informed consent and HIPAA authorization
Adequate organ function
Exclusion Criteria
Inability or refusal to receive systemic therapy
Refusal to permit the study team to obtain follow up information from treating physicians? office or perform in person or remote follow up on available records
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or